Liraglutide is a long-acting analog of GLP-1 approved for the treatment of T2D that has been found to improve cognitive performance, synaptogenesis and mitochondrial biogenesis in animal models of AD [39,40] and PD [41]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.